Search Results
Mar 25, 2026, 07:28 ET PAN GLOBAL REPORTS 29.8 G/T GOLD OVER 3.0 METERS AT PROVIDENCIA AND COMMENCES FOLLOW-UP DRILL PROGRAM, CÁRMENES PROJECT, SPAIN
PtPdID
More news about: Pan Global Resources Inc.
Mar 25, 2026, 07:28 ET PAN GLOBAL REPORTS 29.8 G/T GOLD OVER 3.0 METERS AT PROVIDENCIA AND COMMENCES FOLLOW-UP DRILL PROGRAM, CÁRMENES PROJECT, SPAIN
PtPdID
More news about: Pan Global Resources Inc.
Mar 25, 2026, 06:00 ET HanchorBio Advances Toward TWSE Innovation Board Listing to Accelerate Global Clinical Development, Platform Expansion, and International Partnering
collaboration opportunities. HCB301 is a tri-specific fusion protein developed using the FBDB™ platform and engineered to coordinate SIRPα, PD-L1, and TGF-β modulations within a single molecule. Currently in Phase 1 clinical development, this program reflects HanchorBio's broader capability of
More news about: HanchorBio Inc.
Mar 25, 2026, 05:43 ET Dr. Walter Koroshetz Named to American Parkinson Disease Association Scientific Advisory Board
contributions to Parkinson's disease (PD) initiatives at the National Institutes of Health (NIH). His expertise will help guide APDA's research funding strategy as the organization continues to invest in innovative science aimed at improving the lives of people living with PD and ultimately finding a cure."Dr.
More news about: American Parkinson Disease Association, Inc.
Mar 24, 2026, 22:40 ET Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab
two novel ADC candidates in combination with the Company's pioneering immuno-oncology (IO) 2.0 bispecific antibodies, cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF), as well as other proprietary high-potential anti-tumor assets, including AK117 (anti-CD47 monoclonal antibody) and AK109 (anti-VEGF
More news about: Akeso, Inc.
Mar 24, 2026, 22:34 ET From SCAN to SPARK: Galaxy Brain Scientific Enables a New Paradigm in Non-invasive, Personalized Precision Treatment for Parkinson's Disease
disease (PD) by remodeling the SPARK circuit. (https://www.nature.com/articles/s41593-026-02228-w)The findings build directly on the team's previous identification of a core cortico-subcortical PD circuit
More news about: Galaxy Brain Scientific Inc.
Mar 24, 2026, 13:38 ET 科倫博泰公佈2025年業績：多款產品成功上市，階梯式研發管線蓄勢待發
llipses Pharma正在中國以外的地區推進其2期臨床研究。2025年5月，富馬酸侖博替尼膠囊治療晚期RET突變型甲狀腺髓樣癌的1期研究結果在ASCO年會上公佈。SKB118/CR-001（PD-1/VEGF雙抗）：2026年1月，Crescent Biopharma宣佈其用於治療晚期實體瘤的SKB118新藥臨床試驗申請已獲FDA批准，啟動全球ASCEND 1/2期臨床試驗，首例患者已於2026年2月給藥。公司計劃於2026年上半年在中國啟動SKB118的1/2期臨床研究。
More news about: 科倫博泰
Mar 24, 2026, 10:47 ET Fosun Pharma Announces 2025 Annual Results
treatment option for breast cancer patients; the anti-PD-1 monoclonal antibody Serplulimab Injection was approved in Europe and multiple emerging markets for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), becoming the first anti-PD-1 monoclonal antibody to receive such approval
More news about: Fosun Pharma
Mar 24, 2026, 10:00 ET Q2BI Marks the Independent Launch of JDIX and a New Chapter in Clinical Data Intelligence
company specializing in biometrics, data science, and AI-enabled clinical solutions. With deep expertise across clinical statistics, data management, PK/PD, and regulatory submissions, Q2BI partners with biopharma and AI companies to accelerate the development of innovative medicines.For more information,
More news about: Q-Square Business Intelligence (Q2BI)
Mar 24, 2026, 09:30 ET First Parkinson's Patients Treated in Landmark Phase 2 Trial of Dapansutrile - Expanding a Leading Oral NLRP3 Inhibitor into Neurological Diseases
NLRP3 inhibitors, dapansutrile, today announced that two patients have been randomized in a 12-month clinical trial, named DAPA-PD, for the treatment of Parkinson's disease (PD).
More news about: Olatec Therapeutics, Inc.
Mar 24, 2026, 09:00 ET Parkinson's Foundation Announces 2026 Moving Day Walks
all abilities can unite with a shared purpose: to improve care and accelerate research for PD."Moving Day is an inspiring fundraising event that brings communities together to honor loved ones with PD, celebrate the power of movement and raise critical funds for research and quality care. In the
More news about: Parkinson's Foundation
Mar 24, 2026, 07:57 ET RYBODYN ANNOUNCES SEED FINANCING TO ADVANCE AI-DRIVEN DISCOVERY OF HIDDEN CANCER TARGETS
targets those drugs chase are more crowded than ever. For example, the well-known EGFR target has over 200 drugs approved or in development, and the PD-1/PD-L1 checkpoint axis has nearly 200 more. In an era of intense focus on AI-driven drug design, the bottleneck is no longer the ability to design high-affinity
More news about: RyboDyn
Mar 24, 2026, 05:02 ET Kelun-Biotech Receives IND Approval for SKB103, a Novel TAA-PD-L1 Bispecific ADC
and Immuno-Oncology mechanisms (TAA-PD-L1 bsADC), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of advanced solid tumors. The approval marks SKB103 as the Company's first TAA-PD-L1 bsADC candidate and its second
More news about: Kelun-Biotech
Mar 24, 2026, 04:49 ET 科倫博泰首個TAA-PD-L1雙抗ADC藥物SKB103獲批臨床，新型偶聯藥物戰略加速落地
2026年3月24日 /美通社/ -- 2026年3月24日，四川科倫博泰生物醫藥股份有限公司（「科倫博泰」或「公司」，6990.HK）宣佈，其自主研發的新型TAA-PD-L1雙抗ADC藥物SKB103的新藥臨床試驗（IND）申請已獲國家藥品監督管理局（NMPA）藥品審評中心（CDE）批准，用於治療晚期實體瘤。這是公司首個進入臨床階段的TAA-PD-L1雙抗ADC，也是繼SKB571之後第二款進入臨床階段的用於腫瘤治療的雙抗ADC。
More news about: 科倫博泰
Mar 24, 2026, 03:43 ET DualityBio (9606.HK) Announces 2025 Annual Results
exon 19 deletion or exon 21 L858R mutation whose disease has progressed on or after therapy with an EGFR TKI.DB-1419 (B7-H3×PD-L1 BsADC): Currently the only B7-H3×PD-L1 BsADC under clinical development globally, a global Phase 1/2a trial is being conducted in patients with advanced/metastatic
More news about: Duality Biotherapeutics, Inc.
Mar 24, 2026, 02:20 ET 映恩生物（9606.HK）公佈2025年度業績
合靶點，驗證了其藥理機制。DB-1418/AVZO-1418 (EGFR×HER3 BsADC)：合作夥伴Avenzo已宣佈全球1/2期試驗完成首例晚期實體瘤患者給藥DB-1419 (B7-H3×PD-L1 BsADC)：目前全球唯一處於臨床開發階段的 B7-H3×PD-L1 BsADC，全球1/2a期試驗正在招募晚期/轉移性實體瘤患者。DB-1317 (ADAM9 ADC)：針對胃腸道癌高表達靶點 ADAM9 的下一代 ADC，全球1/1b期試驗正在招募晚期/轉移性實體瘤患者。DB-1324
More news about: Duality Biotherapeutics, Inc.
Mar 23, 2026, 22:31 ET KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF
combination with pembrolizumab for the first-line treatment of PD-L1 positive NSCLC were granted Breakthrough Therapy Designation by the NMPA.The Phase 3 registrational study of sac-TMT in combination with pembrolizumab as first-line treatment of PD-L1 negative NSCLC is in progress.Other
More news about: Kelun-biotech
Mar 23, 2026, 10:16 ET Refurbished and Used Mobile Phones Market to Reach US$ 135.4 Billion by 2033 Expands Amid Circular Economy and Affordable Smartphone Demand - Persistence Market Research
Power over Ethernet (PoE) Solutions Market by Product Type (Power Sourcing Equipment (PSE), Powered Devices (PD)), Device Type (PoE Switches, PoE Injectors, IP Cameras, Wireless Access Points, VoIP Phones, Others), End-Use (Commercial, Residential, Industrial, Others),
More news about: Persistence Market Research Pvt. Ltd.
Mar 23, 2026, 08:41 ET Alzheimer's Disease Data Initiative Doubles $1M Prize Competition for Agentic AI Solutions to Accelerate Alzheimer's Research
judging panel on March 17, 2026, during the Alzheimer's Insights Summit 3 at the 20th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) in Copenhagen. The five finalist teams were:Aletheia (University of Notre Dame, Indiana University School of Medicine)Biomni-AD
More news about: Alzheimer's Disease Data Initiative
Mar 23, 2026, 07:46 ET Bio-Thera Solutions Announces Further Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Exclusive Commercialization and License Agreement in India
EU, a/k/a POBEVCY® in China. In addition, the company has more than 20 promising candidates in clinical trials, focusing on immuno-oncology in the post-PD-1 era and targeted therapies such as antibody-drug conjugates (ADCs). For more information, please visit
More news about: Bio-Thera Solutions, Ltd
Mar 23, 2026, 07:00 ET BioLineRx Reports 2025 Financial Results and Provides Corporate Update
progressive GBM and other high-grade gliomas. The objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Data from the Phase 1 part of the trial are anticipated in H1 2027.The Phase 2a expansion part of the trial is planned
More news about: BioLineRx Ltd.
Mar 23, 2026, 03:54 ET New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
https://news.cision.com/bioarctic/r/new-data-on-long-term--real-world-treatment-with-lecanemab-presented-at-the-2026-ad-pd--congress,c4324952The following files are available for download:
More news about: BioArctic
Mar 23, 2026, 03:50 ET New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
https://news.cision.com/bioarctic/r/new-data-on-long-term--real-world-treatment-with-lecanemab-presented-at-the-2026-ad-pd--congress,c4324952The following files are available for download:
More news about: BioArctic
Mar 22, 2026, 23:44 ET Para Light ने उद्योग-अग्रणी RDS(on) स्थिरता वाले ThermaFlat™ SiC MOSFETs के साथ थर्मल सीमाओं को तोड़ा
मॉडल इस पूरे तापमान अंतराल में लगभग स्थिर प्रतिरोध बनाए रखने के साथ-साथ स्विचिंग हानि को कम-से-कम करता है। इससे भी अधिक उल्लेखनीय उच्च-वोल्टेज प्रस्तुति PD035S120ANC (1200V) है, जो समान तापमान सीमा पर RDS(on) वृद्धि को मात्र 26% तक सीमित करता है - बेहतर सिस्टम विश्वसनीयता, विस्तारित
More news about: Para Light Electronics Co., Ltd.
Mar 22, 2026, 22:20 ET Henlius informa sus resultados de 2025: Crecimiento sostenido tanto en ingresos como en beneficios
Henlius continúa impulsando su cartera de productos innovadores, con activos clave como dulpatatug (HLX22, un nuevo epítopo anti-HER2 mAb) y HLX43 (PD-L1 ADC) que se encuentran en fases clínicas críticas.Gracias a sus capacidades integradas que abarcan I+D, operaciones clínicas, regulación, fabricación
More news about: Henlius